Author: admin

Eimco Elecon (India) Ltd. has announced that its promoter group entity, Tamrock Great Britain Holdings, will exercise an oversubscription option in its ongoing Offer for Sale (OFS), potentially leading to a complete exit from the company. Tamrock, which held a 24.68% stake in the mining and construction equipment…

Luxury fashion platform Purple Style Labs (PSL), the parent company of Pernia’s Pop-Up Shop (PPUS), has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) for a proposed ₹660 crore initial public offering. The company, which operates an omnichannel marketplace for…

TGV SRAAC Limited, a leading player in the chemical sector, has announced the successful commissioning of an additional 5 MWp solar power capacity, taking its overall solar portfolio to 50.4 MWp. The move marks an 11% increase from its earlier capacity of 45.4 MWp and underscores the company’s…

Max India Limited, a diversified player in the healthcare and allied services space, has successfully raised ₹80.35 crore through a preferential issue of 36,19,594 fully convertible warrants at an issue price of ₹222 per warrant. The allotment, approved by the company’s Board on September 24, 2025, includes both…

Kingfa Science & Technology (India) Limited has successfully concluded a preferential allotment of equity shares, raising ₹499.99 crore to fuel its growth initiatives and strengthen its financial position. The company allotted 14,40,920 equity shares at an issue price of ₹3,470 per share, with participation from seven non-promoter investors,…

Newgen Software Technologies Limited has announced two significant contract wins — one in Europe and another in India — that further strengthen its global presence and domestic footprint in digital transformation solutions. €4.22 Million Master Service Agreement in Europe Through its wholly owned UK subsidiary, Newgen signed a…

Glenmark Pharmaceuticals, through its Swiss subsidiary Glenmark Specialty SA, has entered into an exclusive licensing agreement with China’s Hengrui Pharma for Trastuzumab Rezetecan, an advanced antibody drug conjugate (ADC) for cancer therapy. Under the terms of the deal, Glenmark will pay an upfront fee of $18 million, while…

Glenmark Pharma Signs Licensing Deal with Hengrui Pharma Glenmark Pharmaceuticals’ subsidiary, Glenmark Specialty, has entered into an exclusive licensing agreement with Hengrui Pharma for Trastuzumab Rezetecan (SHR-A1811), a HER2-targeting antibody drug conjugate. Newgen Software Bags €4.22 Million TCS Deal Newgen Software Technologies’ subsidiary has signed a five-year Master…